White Papers

1. Empowering Mid-Size Pharma Companies With Integrated Drug Development, Regulatory Strategy, And AI Innovation 10/23/2025

   A consultative, tech-enabled CRO can help mid-size pharma achieve targets by supplementing skillsets, expanding global reach, and designing an effective clinical, regulatory, and operational strategy.

2. Designing More Precise Clinical Trials Using AI-Driven Analytics 10/20/2025

   Clinical trials face staggering failure rates and inefficiencies. Discover how AI and real-world evidence streamline patient recruitment and trial design to help reshape the future of clinical research.

3. What Is ICH GCP, And How Does It Impact Clinical Planning? 10/20/2025

   The updated ICH GCP guideline modernizes clinical trial standards, aligning with today’s technologies to enhance participant safety, data integrity, and risk-based trial design.

4. Clinical Trial Disclosure Noncompliance: What Is Its Impact On Pharma M&As? 10/20/2025

   Noncompliance with clinical trial disclosure regulations can jeopardize M&A deals. Understanding FDA and SEC requirements is critical to avoid red flags during due diligence.

5. Challenges, Opportunities For Recruitment In The Digital Age 10/20/2025

   Health literacy gaps and online misinformation hinder clinical trial recruitment. Meeting patients where they are — digitally and educationally — can improve engagement and enrollment success.

6. Streamlining Patient Recruitment With AI–Driven Site Identification 10/20/2025

   This study highlights the use of an RWD-driven, AI-enabled recruitment models as a transformative strategy for clinical development in hard-to-recruit populations.

7. Streamlining Clinical Trial Start-Up In Australia 10/20/2025

   Gain a comprehensive overview of how sponsors can accelerate clinical trial start-up in Australia, leveraging the nation’s unique strengths as a global hub for clinical research.

8. The EMR Interoperability Dream Vs. Clinical Research Reality 10/20/2025

   Seamless Electronic Medical Record access promises accelerated trials and regulatory-grade evidence, but incomplete, unstructured data requires hybrid strategies using AI and human oversight to bridge gaps.

9. Automating Regulatory-Grade RWE 10/20/2025

   Global regulatory agencies increasingly adopt Real-World Evidence, demanding higher data quality and automated AI-driven platforms to meet evolving standards and improve drug development pathways.

10. The Case For A New Paradigm In Geographic Atrophy Clinical Trials 10/15/2025

    Here, the author introduces a new framework for GA clinical development that integrates genetic profiling, novel biomarkers, and predictive analytics to improve precision, streamline design, and accelerate development.